Therapeutic Response

ER positive, HER2-positive, and PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.

Statements

Source and description
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.